合伙人律师
Carlton Fleming
- 资本市场
- 新兴公司和风险投资
CARLTON FLEMING represents high-growth private and public life sciences and technology companies in a wide range of securities, corporate, investor outreach, disclosure, shareholder engagement and activism, financing and corporate governance matters. He is a member of the firm’s Public Company Advisory steering committee and regularly advises corporate clients and their boards of directors and special committees on a wide variety of securities law and corporate governance matters. Since 2012, Carlton has been involved in over 60 IPOs and other public offerings, helping raise over $11 billion.
经验
- 代理事宜
Carlton’s substantial experience includes the following representative matters:
- Akeso Biopharma in its $5 billion collaboration and licensing agreement with Summit Therapeutics Inc.
- Atara Biotherapeutics, Inc. in its initial public offering and multiple follow-on equity offerings.
- Cornerstone OnDemand, Inc. in its $1.4 billion acquisition of Saba Software.
- Cytokinetics, Incorporated in its US$138 million offering of senior notes, multiple follow-on equity offerings, and royalty financing transactions.
- DocuSign, Inc. in its:
- US$303.0 million Series E financing;
- US$723.7 million initial public offering;
- US$443.3 million follow-on equity offering and concurrent offering US$575 million 0.5% convertible senior notes due 2023; and
- US$188 million acquisition of Seal Software.
- Eiger BioPharmaceuticals, Inc. in multiple follow-on equity offerings.
- Kodiak Sciences Inc. in its:
- US$312 million and US$645 million follow-on equity offerings; and
- US$225 million royalty financing transaction.
- Quotient Technology Inc. in its proxy contest defense against Engaged Capital.
- Lyell Immunopharma, Inc. in its $493 million Series C financing.
- MobileIron, Inc. in its $100.0 million initial public offering.
- NGM Biopharmaceuticals, Inc. in its US$106.7 million initial public offering and US$143.8 million follow-on offering.
- Pliant Therapeutics, Inc. in its US$230.0 million and $287.5 million follow-on equity offerings.
- Prothena Corporation plc in its $183.6 million follow-on equity offering.
- Rigel Pharmaceuticals, Inc. in multiple follow-on equity offerings.
- Talis Biomedical Corporation in its US$232.5 million initial public offering.
- Takeda Pharmaceutical Company Limited in its collaboration with and equity investment in Denali Therapeutics.
- Twilio Inc. in its US$1.8 billion public offering of Class A common stock and US$1.0 billion public offering of senior notes.
- Vaxcyte, Inc. in its US$287.5 million initial public offering.
- Vera Therapeutics, Inc. in its initial public offering.
- Zynga, Inc. in its $527 million acquisition of NaturalMotion.
*Some of the matters above were handled prior to joining Sidley.
相关业务能力
服务
新闻与观点
证书
执业资格及证书
- 美国加州
- North Carolina
学历和教育
- 杜克大学法学院, J.D., LL.M., 2007
- 美国杜克大学, 文学学士, 2004